Underwriting Agreement February 13, 2025Underwriting Agreement • February 19th, 2025 • Digital Ally, Inc. • Radio & tv broadcasting & communications equipment • New York
Digital Ally, Inc., a Nevada corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 100,000,000 of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock, $0.001 par value per share, of the Company (the “Common Stock”); one (1) Series A warrant (“Series A Warrant”) to purchase one (1) share of Common Stock at a per share exercise price of $0.1875 (representing 125.0% of the per Closing Common Unit (as defined below) offering price) and one (1) Series B warrant (“Series B Warrant”) to purchase one (1) share of Common Stock at a per share exercise price of $0.3000 (representing 200.0% of the per Closing Common Unit offering price) (each, a “Closing Common Unit”); or (B) one (1) pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share of Common Stock at an exercise price
UNDERWRITING AGREEMENT February 5, 2025Underwriting Agreement • February 6th, 2025 • Volcon, Inc. • Motor vehicles & passenger car bodies • New York
Volcon, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 6,000,000 of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock, $0.00001 par value per share of the Company (the “Common Stock”) and one (1) warrant to purchase one (1) share of Common Stock at a per Share exercise price of $2.00 (representing 100.0% of the per Closing Common Unit (as defined below) offering price attributed to the value of the shares of Common Stock included in the Closing Common Unit) (each, a “Closing Common Unit”); or (B) one (1) pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share of Common Stock at an exercise price of $0.00001 and one (1) warrant to purchase one (1) share of Common Stock at a per-Share exercise price of $2.00 (representing 100.0% of the per
UNDERWRITING AGREEMENT January 6, 2025Underwriting Agreement • January 7th, 2025 • AEON Biopharma, Inc. • Pharmaceutical preparations • New York
AEON Biopharma, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 40,000,000 of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock of the Company, $0.0001 par value per share (the “Common Stock”); one (1) Series A warrant (“Series A Warrant”) to purchase one (1) share of Common Stock at a per share exercise price of $0.625 (representing 125.0% of the Closing Common Unit (as defined below) offering price) and one (1) Series B warrant (“Series B Warrant”) to purchase one (1) share of Common Stock at a per share exercise price of $0.625 (representing 125.0% of the Closing Common Unit offering price) (each, a “Closing Common Unit”); or (B) one (1) pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share of Common Stock at an exercise price of $0.
UNDERWRITING AGREEMENT April 4, 2024Underwriting Agreement • April 8th, 2024 • Flora Growth Corp. • Pharmaceutical preparations • New York
FLORA GROWTH CORP., an Ontario corporation (the "Company"), agrees, subject to the terms and conditions in this agreement (this "Agreement"), to issue and sell to Aegis Capital Corp. (the "Underwriter") an aggregate of 1,700,000 of the Company's Common Shares, without par value per share ("Common Shares"; such offered Common Shares the "Shares"). The number of Shares to be purchased by the Underwriter is set forth opposite its name in Schedule 4.1.2 hereto. Aegis Capital Corp. has agreed to act as the Underwriter in connection with the offering and sale of the Securities.
Underwriting AgreementUnderwriting Agreement • October 12th, 2022 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
Underwriting AgreementUnderwriting Agreement • September 16th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • New York